The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
about
The blind men and the AML elephant: can we feel the progress?Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive TherapiesAn update of current treatments for adult acute myeloid leukemiaVolasertib for AML: clinical use and patient considerationDistribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Acute myeloid leukemia: 2014 update on risk-stratification and management.Management of older or unfit patients with acute myeloid leukemiaEarly versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemiaGemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.Is targeted therapy feasible in acute myelogenous leukemia?Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinThe prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalitiesDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Emerging immunotherapies in older adults with acute myeloid leukemia.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?Acute myeloid leukemia in the elderly: do we know who should be treated and how?Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.Frontline therapy of AML: should the older patient be treated differently?Gemtuzumab ozogamicin in acute myeloid leukemia revisited.Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.Novel drugs for older patients with acute myeloid leukemia.Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia.An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.Update on antigen-specific immunotherapy of acute myeloid leukemia.Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.Novel drug therapies in myeloid leukemia.Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials.Acute myeloid leukemia in the elderly: therapeutic options and choice.Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
P2860
Q26749614-2BC7FD23-C36B-48D1-9CCC-DFA8FCE92CEBQ26772235-B957FC50-75EE-4DDF-9E1B-988851F5CBC6Q26776396-C63D88BF-DFCE-40E7-8B26-8F22492470AEQ26801131-C704ED80-0F07-47E1-B3B3-AFDF359B06D3Q27853019-BB4FD4B9-CF94-40EF-B664-5020ECBC82D7Q30275229-160341BE-C950-4FF2-B275-71D37E8D8632Q30835785-73E0BE76-0FC8-4926-BF04-37EF3F9B3F5DQ34665691-E712F727-F843-4F6B-A903-F5CB36F72614Q34893307-508865FB-788A-4346-934D-0BD1EDE4CE33Q34937415-370D935D-09C7-41E9-98E4-282FEA804563Q35606252-2C17352A-4300-4559-B363-31435D7C62C4Q35954771-AA37E683-F903-49A1-BC96-461F9B663951Q36416358-C6055DA9-DE2E-4E69-91FB-E99D3A9582F2Q36498399-75825325-FA9D-45F2-BEA5-AD338DD2C796Q36682845-616A8751-05A3-4639-96C1-A551E5D529E2Q36716744-2357F447-7DE6-4B8D-9B7F-BF5DDF37D8CEQ36914445-77AAED4E-516D-4C78-998E-7F03965F1DD1Q36932014-917256D1-BB66-415D-AD5E-195A7CB2CC0FQ37396005-70B8C00D-0CCC-4FBC-AFBB-60E3B28C7C00Q37624593-66D5E38A-9CFB-47A3-B005-07F2C46860DAQ37643136-B476877C-87BC-445C-A938-607A66596908Q38075407-AA92C9B2-94FB-4D5C-9A74-8FE7DE785716Q38091393-25CB6DC3-A72A-46FD-A65A-341F2DEA25C7Q38124066-AB1D9C33-0F5E-4D74-B62F-306A4E115E74Q38183359-2A467DCD-0F70-4443-AE02-1203645E5350Q38183943-B213E485-A3B3-43B5-9F0C-EE51FBB2ADAAQ38212586-0C02610F-5244-4645-B2D2-3EA009F8CB42Q38215269-EF3D59BA-00DE-4611-A305-1997277587ABQ38232465-E77B5979-F3F0-44D4-B0F1-E41323BE8B93Q38241761-81C8845E-82E6-4EC4-A965-11DBFA2FB225Q38256888-A10FD266-E70F-4EEA-A9C5-98851E664A8BQ38285621-57E3D281-325D-4745-901B-CFF80792BD80Q38432103-A5F4FAD2-2EED-42FF-8E24-D5160FAE1877Q38469793-4ADBD390-2871-4316-AF55-CF3DBF919DC5Q38510486-780FEED2-CAA2-4FB5-9A07-547D4E518D7AQ38537879-A8AD9A46-88CC-435F-81F7-903CABDACF02Q38601723-A953FA1E-2670-462E-958B-C3022FB3F52FQ38642017-5AD2E0D7-391E-408D-937C-DD542DAEDCD4Q38675781-AC08DC65-0C42-4DB1-8043-4035539B11C7Q38707852-0E7F04C8-01A2-49C3-BD8C-16969FCBFDB5
P2860
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The addition of gemtuzumab ozo ...... ML16 pick-a-winner comparison.
@en
The addition of gemtuzumab ozo ...... ML16 pick-a-winner comparison.
@nl
type
label
The addition of gemtuzumab ozo ...... ML16 pick-a-winner comparison.
@en
The addition of gemtuzumab ozo ...... ML16 pick-a-winner comparison.
@nl
prefLabel
The addition of gemtuzumab ozo ...... ML16 pick-a-winner comparison.
@en
The addition of gemtuzumab ozo ...... ML16 pick-a-winner comparison.
@nl
P2093
P2860
P356
P1433
P1476
The addition of gemtuzumab ozo ...... ML16 pick-a-winner comparison.
@en
P2093
A E Hunter
A K Burnett
D Milligan
K Wheatley
M F McMullin
N H Russell
UK National Cancer Research Institute AML Working Group
P2860
P2888
P356
10.1038/LEU.2012.229
P577
2012-08-14T00:00:00Z